Hydroxamic acid derivatives

A pharmaceutical composition comprising:

• (i) a therapeutically effective amount of the compound of formula I:
• ##STR13## or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• X is ##STR14## Y is CR.sub.1 R.sub.2 ;
• R, R.sub.1, and R.sub.2 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.9 straight or branched chain alkyl, C.sub.2 -C.sub.9 straight or branched chain alkenyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.7 cycloalkenyl and Ar;
• and
• Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, benzyl, and phenyl, said Ar having one to three substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C.sub.1 -C.sub.6 straight or branched chain alkyl, C.sub.2 -C.sub.6 straight or branched chain alkenyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy, phenoxy, benzyloxy and amino;
• and
• (ii) a pharmaceutically acceptable carrier.

A method of inhibiting NAALADase enzyme activity in a mammal in need of such treatment, comprising administering an effective amount of the compound of formula I:

• ##STR15## or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• X is ##STR16## Y is CR.sub.1 R.sub.2 ;
• R, R.sub.1, and R.sub.2 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 straight or branched chain alkyl, C.sub.2 -C.sub.9 straight or branched chain alkenyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.7 cycloalkenyl and Ar;
• and
• Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, benzyl, and phenyl, said Ar having one to three substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C.sub.1 -C.sub.6 straight or branched chain alkyl, C.sub.2 -C.sub.6 straight or branched chain alkenyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy, phenoxy, benzyloxy and amino, in admixture with a pharmaceutically acceptable carrier or diluent, to said mammal.

A method of treating a glutamate abnormality in a mammal in need of such treatment, comprising administering an effective amount of the compound of formula I:

• ##STR17## or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• X is ##STR18## Y is CR.sub.1 R.sub.2 ;
• R, R.sub.1, and R.sub.2 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.9 straight or branched chain alkyl, C.sub.2 -C.sub.9 straight or branched chain alkenyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.7 cycloalkenyl and Ar;
• and
• Ar is selected from the Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, benzyl, and phenyl, said Ar having one to three substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C.sub.1 -C.sub.6 straight or branched chain alkyl, C.sub.2 -C.sub.6 straight or branched chain alkenyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy, phenoxy, benzyloxy and amino, in admixture with a pharmaceutically acceptable carrier or diluent, to said mammal.

A method of treating a prostate disease in a mammal, comprising administering an effective amount of the compound of formula I:

• ##STR19## or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• X is ##STR20## Y is CR.sub.1 R.sub.2 ;
• R, R.sub.1, and R.sub.2 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.9 straight or branched chain alkyl, C.sub.2 -C.sub.9 straight or branched chain alkenyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.7 cycloalkenyl and Ar;
• and
• Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, benzyl, and phenyl, said Ar having one to three substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C.sub.1 -C.sub.6 straight or branched chain alkyl, C.sub.2 -C.sub.6 straight or branched chain alkenyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy, phenoxy, benzyloxy and amino, in admixture with a pharmaceutically acceptable carrier or diluent, to said mammal.